Review
Microbiology
Christina S. Thornton, Michael G. Surette
Summary: Cystic fibrosis is the most common and lethal genetic disease among the Caucasian population, leading to chronic airway inflammation and declining pulmonary function. Studies have shown a diverse community of anaerobic bacteria in CF patients' airways, potentially impacting disease progression through synergistic interaction with principal pathogens. Despite the understanding of this complex bacterial milieu, the specific roles of anaerobes in disease progression remain unclear.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Microbiology
Xuerui Bao, Mona Bove, Tom Coenye
Summary: The high tolerance of Pseudomonas aeruginosa biofilms in respiratory tract infections in cystic fibrosis contributes to the failure of antibiotic therapy. This study identified carbon sources that could enhance the inhibiting and/or eradicating activity of tobramycin, ciprofloxacin, and ceftazidime against P. aeruginosa PAO1 biofilms. The mechanisms underlying the enhanced biofilm eradicating activity were strain-dependent.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Immunology
Veronica Roxana Flores-Vega, Silvia Yalid Vargas-Roldan, Jose Luis Lezana-Fernandez, Ricardo Lascurain, Jose Ignacio Santos-Preciado, Roberto Rosales-Reyes
Summary: Cystic fibrosis is a genetic disease caused by a mutation in the cftr gene, affecting chloride ion and water transport and leading to bacterial infections in the lungs. Autophagy plays a crucial role in pathogen clearance, but P. aeruginosa and B. cenocepacia have strategies to evade this pathway, resulting in chronic inflammatory immune responses.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Microbiology
Chun-Yu Lin, Hung-Yu Huang, Meng-Heng Hsieh, Yueh-Fu Fang, Yu-Lun Lo, Shu-Min Lin, Yu-Tung Huang, Chih-Hsin Yeh, Chun-Hua Wang, Horng-Chyuan Lin
Summary: This study investigated the impact of nontuberculous mycobacteria (NTM) in non-cystic fibrosis bronchiectasis in Taiwan. The results showed that NTM were associated with frequent exacerbations and mortality in non-cystic fibrosis bronchiectasis patients, especially when coexisting with Pseudomonas aeruginosa and fungus. Additionally, the presence of single or multiple NTM isolates was an independent risk factor for mortality.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Immunology
Jonathan D. Cogen, Anna Faino, Frankline Onchiri, Lucas R. Hoffman, Matthew P. Kronman, David P. Nichols, Margaret Rosenfeld, Ronald L. Gibson
Summary: A retrospective cohort study found that there were no significant differences in respiratory and clinical outcomes between young patients with cystic fibrosis treated with one versus two intravenous antipseudomonal antibiotics for pulmonary exacerbations.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Ijeoma N. Okoliegbe, Karolin Hijazi, Kim Cooper, Corinne Ironside, Ian M. Gould
Summary: This study compared the in vitro activity of new antimicrobials with other antipseudomonal agents and found colistin to be one of the most active antimicrobials, while combinations with beta-lactam plus beta-lactamase inhibitors showed synergistic effects. The study also highlights the importance of effective fluoroquinolone stewardship for CF patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Giovanni Di Bonaventura, Veronica Lupetti, Simone De Fabritiis, Alessandra Piccirilli, Annamaria Porreca, Marta Di Nicola, Arianna Pompilio
Summary: This study evaluated the antibacterial and antivirulence activities of eight FDA-approved non-antibiotic drugs and their effects on biofilm formation. Ciclopirox and actinomycin D showed the best antibacterial activity and were most effective against preformed biofilms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Medicine, Research & Experimental
Roberto Rosales-Reyes, Veronica Roxana Flores-Vega, Jose Luis Lezana-Fernandez, Jose Ignacio Santos-Preciado
Summary: Pseudomonas aeruginosa is a significant pathogen causing lung infections in patients with cystic fibrosis. Its increasing antibiotic resistance makes treatment challenging. Microbiology and whole genome sequencing are important tools for determining antimicrobial susceptibility and resistance as well as analyzing genomic variations. Molecular epidemiologic surveillance aids in developing better treatment strategies and controlling the spread of Pseudomonas aeruginosa variants.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Immunology
Jonathan D. Cogen, Frankline M. Onchiri, Nicole Mayer Hamblett, Ronald L. Gibson, Wayne J. Morgan, Margaret Rosenfeld
Summary: The study showed that prolonged use of oral antibiotics in children with cystic fibrosis increased the risk of acquiring Achromobacter xylosoxidans, while treatment with intravenous antibiotics was associated with an increased risk of acquiring multidrug-resistant Pseudomonas aeruginosa and MRSA.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Giovanni Di Bonaventura, Veronica Lupetti, Fabio Verginelli, Sara Giancristofaro, Rosemary Barbieri, Giovanni Gherardi, Arianna Pompilio
Summary: This study evaluated the antibacterial, antibiofilm, and antivirulence activities of apramycin compared to tobramycin against P. aeruginosa in cystic fibrosis patients. Apramycin showed better efficacy than tobramycin, without cytotoxicity to bronchial epithelial CF cells.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Nutrition & Dietetics
Aleksandra John, Joanna Gozdzik-Spychalska, Magdalena Durda-Masny, Wojciech Czainski, Natalia Pawlowska, Jolanta Wlizlo, Halina Batura-Gabryel, Anita Szwed
Summary: The study described the relationship between the prevalence of Pseudomonas aeruginosa (PA) and lung function, nutritional status, and gene mutation type in adult patients with cystic fibrosis (CF). The presence of PA was associated with lower FEV1% and BMI values. Severe gene mutation, undernutrition, and deterioration of lung function were linked to a higher probability of PA acquisition and resistance to antibiotic treatment.
Review
Medicine, Research & Experimental
Roberto Rosales-Reyes, Silvia Yalid Vargas-Roldan, Jose Luis Lezana-Fernandez, Jose Ignacio Santos-Preciado
Summary: Cystic fibrosis is a genetic disease that affects the respiratory and digestive systems, causing chronic lung infections and breathing difficulties. Mutations in the CFTR gene lead to imbalanced intracellular water content, resulting in sticky mucus and bacterial infections that ultimately affect lung function.
ARCHIVES OF MEDICAL RESEARCH
(2021)
Article
Microbiology
Samantha L. Durfey, Sudhakar Pipavath, Anna Li, Anh T. Vo, Anina Ratjen, Suzanne Carter, Sarah J. Morgan, Matthew C. Radey, Brenda Grogan, Stephen J. Salipante, Michael J. Welsh, David A. Stoltz, Christopher H. Goss, Edward F. McKone, Pradeep K. Singh
Summary: Studies show that chronic CF infections may persist despite improvements induced by CFTR modulators and aggressive antibiotic treatment. Combining CFTR modulators with intensive antibiotics may be most effective for patients with higher CFTR activity. Challenges remain in improving the health of people with CF.
Review
Immunology
Lalitha Biswas, Friedrich Goetz
Summary: Cystic fibrosis is a genetic disorder characterized by recurrent lung infections caused by Staphylococcus aureus and Pseudomonas aeruginosa. The interactions between these pathogens play a significant role in their survival, antibiotic resistance, and disease progression. Understanding these interactions is crucial for the treatment and prevention of cystic fibrosis.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Infectious Diseases
Vaughn D. Craddock, Evan L. Steere, Hannah Harman, Nicholas S. Britt
Summary: Delafloxacin (DLX) is a newly approved fluoroquinolone that shows broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). DLX exhibits excellent penetration in the CF lung and has enhanced activity in low pH environments. In this study, DLX was compared to ciprofloxacin (CPX) and levofloxacin (LVX) against Psa strains isolated from CF sputum. DLX showed significant improvements in killing bacteria in a CF sputum time-kill model at physiologically relevant drug concentrations, making it a potential option for treating MDR-Psa pulmonary infections in CF patients.
Article
Pediatrics
Andrew M. Jones
PAEDIATRIC RESPIRATORY REVIEWS
(2019)
Editorial Material
Pediatrics
Andrew M. Jones
PAEDIATRIC RESPIRATORY REVIEWS
(2019)
Review
Pediatrics
Elizabeth A. Clarke, Pippa Watson, Jane E. Freeston, Daniel G. Peckham, Andrew M. Jones, Alex Horsley
PEDIATRIC PULMONOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Yasmine Fathy Mohamed, Nichollas E. Scott, Antonio Molinaro, Carole Creuzenet, Ximena Ortega, Ganjana Lertmemongkolchai, Michael M. Tunney, Heather Green, Andrew M. Jones, David DeShazer, Bart J. Currie, Leonard J. Foster, Rebecca Ingram, Cristina De Castro, Miguel A. Valvano
JOURNAL OF BIOLOGICAL CHEMISTRY
(2019)
Article
Respiratory System
Amy Coward, Dervla T. D. Kenna, Neil Woodford, Jane F. Turton, Malcolm Armstrong, Cressida Auckland, Ian Bowler, Phillipa Burns, James Cargill, Mary Carroll, William Flight, Michelle Graver, Heather Green, Carolyne Horner, Andrew Jones, Andrew M. Jones, Graeme Jones, Sarah Mayell, Jeorge Orendi, Audrey Perry, Ali Robb, Natasha Tucker, David Waine, Trevor Winstanley, Nick Withers
JOURNAL OF CYSTIC FIBROSIS
(2020)
Article
Respiratory System
James Reihill, Kelly Moffitt, Lisa Douglas, J. Stuart Elborn, Andrew Jones, S. Lorraine Martin
JOURNAL OF CYSTIC FIBROSIS
(2020)
Article
Multidisciplinary Sciences
Alex R. Horsley, Amnah Alrumuh, Brooke Bianco, Katie Bayfield, Joanne Tomlinson, Andrew Jones, Anirban Maitra, Steve Cunningham, Jaclyn Smith, Catherine Fullwood, Anand Pandyan, Francis J. Gilchrist
Editorial Material
Pediatrics
Andrew M. Jones
PAEDIATRIC RESPIRATORY REVIEWS
(2020)
Article
Pediatrics
J. A. Scott, P. J. Barry, A. M. Jones, V. S. Athwal
PAEDIATRIC RESPIRATORY REVIEWS
(2020)
Article
Respiratory System
Jordan B. Dennis, Andrew M. Jones, Emma A. Davies, William Welfare, Peter J. Barry, Lisa Collier, Andrew Turner, Rowland J. Bright-Thomas
JOURNAL OF CYSTIC FIBROSIS
(2020)
Review
Gastroenterology & Hepatology
Jennifer Scott, Andrew M. Jones, Karen Piper Hanley, Varinder S. Athwal
Summary: This review provides a summary of the current understanding of cystic fibrosis-related liver disease (CFLD) in terms of its epidemiology, pathology, diagnosis, and management. The review highlights the heterogeneity of CFLD and the challenges in its diagnosis and treatment. The authors emphasize the lack of precise diagnostic strategies and effective therapies for CFLD, and the need for further research on its pathogenesis and disease detection.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Rosemary E. Maher, Emma Barrett, Robert J. Beynon, Victoria M. Harman, Andrew M. Jones, Paul S. McNamara, Jaclyn A. Smith, Robert W. Lord
Summary: This study aimed to investigate differences in the CF sputum proteome associated with disease severity and identify potential markers of disease with translational potential. Predictable changes in the CF sputum proteome occurred associated with progressive lung function impairment, which might have value as markers of disease severity.
RESPIRATORY MEDICINE
(2022)
Article
Respiratory System
L. R. Caley, C. Zagoya, F. Duckstein, H. White, D. Shimmin, A. M. Jones, J. Barrett, J. L. Whitehouse, R. A. Floto, J. G. Mainz, D. G. Peckham
Summary: This study compared gastrointestinal symptoms in patients with cystic fibrosis and cystic fibrosis-related diabetes. It found that individuals with cystic fibrosis-related diabetes have a higher burden of gastrointestinal symptoms, particularly bloating and nausea.
JOURNAL OF CYSTIC FIBROSIS
(2023)
Article
Respiratory System
Daniel H. Tewkesbury, Varinder Athwal, Rowland J. Bright-Thomas, Andrew M. Jones, Peter J. Barry
Summary: E/T/I therapy leads to a mild and likely clinically insignificant increase in liver tests, which does not appear to further increase in the majority of patients. Underlying CF related liver disease should not be a barrier to treatment.
JOURNAL OF CYSTIC FIBROSIS
(2023)
Review
Medicine, General & Internal
Robert Lord, Andrew M. Jones, Alex Horsley
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2020)